Pfizer (PFE) Retained Earnings (2009 - 2026)

Pfizer has disclosed Retained Earnings across 18 years of filings, most recently posting -$7.2 billion for Q1 2026.

• In Q1 2026, Retained Earnings rose 16.06% year-over-year to -$7.2 billion; the TTM figure through Mar 2026 stood at -$7.2 billion (up 16.06% YoY), while the FY2025 annual figure was $114.6 billion, up 1561.49% from the prior year.
• Retained Earnings eased to -$7.2 billion in Q1 2026, from $114.6 billion in the prior quarter.
• Over the last five years, Retained Earnings for PFE reached as high as $126.4 billion in Q4 2023 and fell as low as -$8.6 billion in Q1 2025.
• The 5-year median for Retained Earnings is -$7.8 billion (2024), against an average of $29.4 billion.
• Annual changes were most pronounced in 2022 — Retained Earnings sank 108.04% — and 2023, when it soared 1636.91%.
• A 5-year view of Retained Earnings shows it stood at -$8.3 billion in 2022, then surged by 1525.25% to $118.4 billion in 2023, then slumped by 106.63% to -$7.8 billion in 2024, then soared by 1561.49% to $114.6 billion in 2025, then tumbled by 106.28% to -$7.2 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$7.2 billion, $114.6 billion, and -$8.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.